Are we reaching the maximum cure rate for Hodgkin lymphoma?

The treatment of Hodgkin lymphoma, using cytotoxic chemotherapy and selective radiotherapy, has resulted in progressively increasing cure rates over the last 40 years. Recent studies have been directed at using response‐adapted approaches to modulate treatment according to the responses seen using f...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2023-06, Vol.41 (S1), p.57-61
Main Author: Johnson, Peter W. M.
Format: Article
Language:English
Subjects:
antibody‐drug conjugate
checkpoint blocking antibody
chemotherapy
Composite Resins - therapeutic use
FDG‐PET
Hodgkin Disease - drug therapy
Hodgkin lymphoma
Humans
Immunoconjugates - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3550-6000966b5b746206c6fe5ace1a02a9e98b284fad07082c6149d4807ed2c454623
cites cdi_FETCH-LOGICAL-c3550-6000966b5b746206c6fe5ace1a02a9e98b284fad07082c6149d4807ed2c454623
container_end_page 61
container_issue S1
container_start_page 57
container_title Hematological oncology
container_volume 41
creator Johnson, Peter W. M.
description The treatment of Hodgkin lymphoma, using cytotoxic chemotherapy and selective radiotherapy, has resulted in progressively increasing cure rates over the last 40 years. Recent studies have been directed at using response‐adapted approaches to modulate treatment according to the responses seen using functional imaging, with the aim of balancing the probability of cure against the toxicity of more extensive treatments, in particular the risks of infertility, second malignancy and cardiovascular disease. The results of these studies suggest that we have reached the limits of what might be expected from the conventional treatments, but the arrival of antibody‐based therapies, specifically antibody‐drug conjugates and immune checkpoint blocking antibodies, now holds out the prospect of further improvements. The next challenge will be to select those groups for whom they are most needed.
doi_str_mv 10.1002/hon.3140
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2824692230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2824692230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3550-6000966b5b746206c6fe5ace1a02a9e98b284fad07082c6149d4807ed2c454623</originalsourceid><addsrcrecordid>eNp1kLFOwzAQQC0EoqUg8QXII0vK2XEcWwyoqoAiVXSB2XIcpwnESbEblf49KS0wMd1w795JD6FLAmMCQG_KthnHhMERGhKQMiLA5TEaAk1FBDSmA3QWwhtAvwNxigZxSiWTXAzR7cRbvLHYW23KqlnidWmx05-V6xw2Xb_0em1x0Xo8a_Ple9XgeutWZev03Tk6KXQd7MVhjtDrw_3LdBbNF49P08k8MnGSQMR3fznPkixlnAI3vLCJNpZooFpaKTIqWKFzSEFQwwmTOROQ2pwalvQX8Qhd770r3350NqyVq4Kxda0b23ZBUUEZl5TG8Ica34bgbaFWvnLabxUBtUul-lRql6pHrw7WLnM2_wV_2vRAtAc2VW23_4rUbPH8LfwC43xv5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2824692230</pqid></control><display><type>article</type><title>Are we reaching the maximum cure rate for Hodgkin lymphoma?</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Johnson, Peter W. M.</creator><creatorcontrib>Johnson, Peter W. M.</creatorcontrib><description>The treatment of Hodgkin lymphoma, using cytotoxic chemotherapy and selective radiotherapy, has resulted in progressively increasing cure rates over the last 40 years. Recent studies have been directed at using response‐adapted approaches to modulate treatment according to the responses seen using functional imaging, with the aim of balancing the probability of cure against the toxicity of more extensive treatments, in particular the risks of infertility, second malignancy and cardiovascular disease. The results of these studies suggest that we have reached the limits of what might be expected from the conventional treatments, but the arrival of antibody‐based therapies, specifically antibody‐drug conjugates and immune checkpoint blocking antibodies, now holds out the prospect of further improvements. The next challenge will be to select those groups for whom they are most needed.</description><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3140</identifier><identifier>PMID: 37294968</identifier><language>eng</language><publisher>England</publisher><subject>antibody‐drug conjugate ; checkpoint blocking antibody ; chemotherapy ; Composite Resins - therapeutic use ; FDG‐PET ; Hodgkin Disease - drug therapy ; Hodgkin lymphoma ; Humans ; Immunoconjugates - therapeutic use</subject><ispartof>Hematological oncology, 2023-06, Vol.41 (S1), p.57-61</ispartof><rights>2023 The Authors. Hematological Oncology published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3550-6000966b5b746206c6fe5ace1a02a9e98b284fad07082c6149d4807ed2c454623</citedby><cites>FETCH-LOGICAL-c3550-6000966b5b746206c6fe5ace1a02a9e98b284fad07082c6149d4807ed2c454623</cites><orcidid>0000-0003-2306-4974</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37294968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johnson, Peter W. M.</creatorcontrib><title>Are we reaching the maximum cure rate for Hodgkin lymphoma?</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><description>The treatment of Hodgkin lymphoma, using cytotoxic chemotherapy and selective radiotherapy, has resulted in progressively increasing cure rates over the last 40 years. Recent studies have been directed at using response‐adapted approaches to modulate treatment according to the responses seen using functional imaging, with the aim of balancing the probability of cure against the toxicity of more extensive treatments, in particular the risks of infertility, second malignancy and cardiovascular disease. The results of these studies suggest that we have reached the limits of what might be expected from the conventional treatments, but the arrival of antibody‐based therapies, specifically antibody‐drug conjugates and immune checkpoint blocking antibodies, now holds out the prospect of further improvements. The next challenge will be to select those groups for whom they are most needed.</description><subject>antibody‐drug conjugate</subject><subject>checkpoint blocking antibody</subject><subject>chemotherapy</subject><subject>Composite Resins - therapeutic use</subject><subject>FDG‐PET</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin lymphoma</subject><subject>Humans</subject><subject>Immunoconjugates - therapeutic use</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kLFOwzAQQC0EoqUg8QXII0vK2XEcWwyoqoAiVXSB2XIcpwnESbEblf49KS0wMd1w795JD6FLAmMCQG_KthnHhMERGhKQMiLA5TEaAk1FBDSmA3QWwhtAvwNxigZxSiWTXAzR7cRbvLHYW23KqlnidWmx05-V6xw2Xb_0em1x0Xo8a_Ple9XgeutWZev03Tk6KXQd7MVhjtDrw_3LdBbNF49P08k8MnGSQMR3fznPkixlnAI3vLCJNpZooFpaKTIqWKFzSEFQwwmTOROQ2pwalvQX8Qhd770r3350NqyVq4Kxda0b23ZBUUEZl5TG8Ica34bgbaFWvnLabxUBtUul-lRql6pHrw7WLnM2_wV_2vRAtAc2VW23_4rUbPH8LfwC43xv5w</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Johnson, Peter W. M.</creator><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2306-4974</orcidid></search><sort><creationdate>202306</creationdate><title>Are we reaching the maximum cure rate for Hodgkin lymphoma?</title><author>Johnson, Peter W. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3550-6000966b5b746206c6fe5ace1a02a9e98b284fad07082c6149d4807ed2c454623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>antibody‐drug conjugate</topic><topic>checkpoint blocking antibody</topic><topic>chemotherapy</topic><topic>Composite Resins - therapeutic use</topic><topic>FDG‐PET</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin lymphoma</topic><topic>Humans</topic><topic>Immunoconjugates - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnson, Peter W. M.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnson, Peter W. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are we reaching the maximum cure rate for Hodgkin lymphoma?</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2023-06</date><risdate>2023</risdate><volume>41</volume><issue>S1</issue><spage>57</spage><epage>61</epage><pages>57-61</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><abstract>The treatment of Hodgkin lymphoma, using cytotoxic chemotherapy and selective radiotherapy, has resulted in progressively increasing cure rates over the last 40 years. Recent studies have been directed at using response‐adapted approaches to modulate treatment according to the responses seen using functional imaging, with the aim of balancing the probability of cure against the toxicity of more extensive treatments, in particular the risks of infertility, second malignancy and cardiovascular disease. The results of these studies suggest that we have reached the limits of what might be expected from the conventional treatments, but the arrival of antibody‐based therapies, specifically antibody‐drug conjugates and immune checkpoint blocking antibodies, now holds out the prospect of further improvements. The next challenge will be to select those groups for whom they are most needed.</abstract><cop>England</cop><pmid>37294968</pmid><doi>10.1002/hon.3140</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-2306-4974</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0278-0232
ispartof Hematological oncology, 2023-06, Vol.41 (S1), p.57-61
issn 0278-0232
1099-1069
language eng
recordid cdi_proquest_miscellaneous_2824692230
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)
subjects antibody‐drug conjugate
checkpoint blocking antibody
chemotherapy
Composite Resins - therapeutic use
FDG‐PET
Hodgkin Disease - drug therapy
Hodgkin lymphoma
Humans
Immunoconjugates - therapeutic use
title Are we reaching the maximum cure rate for Hodgkin lymphoma?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A38%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20we%20reaching%20the%20maximum%20cure%20rate%20for%20Hodgkin%20lymphoma?&rft.jtitle=Hematological%20oncology&rft.au=Johnson,%20Peter%20W.%20M.&rft.date=2023-06&rft.volume=41&rft.issue=S1&rft.spage=57&rft.epage=61&rft.pages=57-61&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3140&rft_dat=%3Cproquest_cross%3E2824692230%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3550-6000966b5b746206c6fe5ace1a02a9e98b284fad07082c6149d4807ed2c454623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2824692230&rft_id=info:pmid/37294968&rfr_iscdi=true